Equities analysts at Cavendish took notice of an eye-catching piece of research on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)’s flagship immunotherapy asset today.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) hailed research indicating a market opportunity exceeding $10 billion POLB 001, which has the potential to combat a common side-effect of cancer immunotherapy treatments.
An independent team reckons the orally administered drug could revolutionise the management of cytokine release syndrome (CRS), particularly in rare and orphan blood cancers.
Maintaining a target price of 19p for Poolbeg Pharma, Cavendish reiterated its confidence in POLB 001's market trajectory following the newly published research.
The asset's broad applicability, underpinned by solid scientific evidence, positions it as a key player in the fight against cancer immunotherapy-induced CRS and beyond, reckon analysts.
They stated: “Even within oncology, it is worth noting that cancer immunotherapies have been approved in several rare and orphan blood cancers which underpins the market opportunity for POLB 001 in one or more of these cancer types.
“In our view, POLB 001’s potentially broad application in both oncology and severe influenza should further enhance its value.”
Poolbeg shares added 4.5% to 9.8p as of 1pm GMT.